NCT03881735 - Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation | Biotech Hunter

Timeline

Start Date

December 2, 2019

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2022

Conditions

Blasts Under 5 Percent of Peripheral Blood White CellsBone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelIDH2 Gene MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Enasidenib

Given PO

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

Trial Locations (2)

11548

Cancer Institute at St Francis Hosptial, East Hills

14263

Roswell Park Cancer Institute, Buffalo